Author(s): Villeneuve S; Poirier J; Breitner JCS; Tremblay-Mercier J; Remz J; Raoult JM; Yakoub Y; Gallego-Rudolf J; Qiu T; Valdez AF; Mohammediyan B; Javanray M; Metz A; Sanami S; Ourry V; Wearn A; Pastor-Bernier A; Edde M; Gonneaud J; Strikwerda- ...

The PREVENT-AD is an investigator-driven study that was created in 2011 and enrolled cognitively normal older adults with a family history of sporadic AD. Participants are deeply phenotyped and have now been followed annually for more than 12 years [median follow-up 8.0 years,SD 3.1]. Multimodal ...

Article GUID: 40778177

Author(s): Farahani A; Liu ZQ; Ceballos EG; Hansen JY; Wennberg K; Zeighami Y; Dadar M; Gauthier CJ; Dagher A; Misic B;

Blood perfusion delivers oxygen and nutrients to all cells, making it a fundamental feature of brain organization. How cerebral blood perfusion maps onto micro-, meso- and macro-scale brain structure and function is therefore a key question in neuroscience. Here we analyze pseudo-continuous arter ...

Article GUID: 40729400

Author(s): Parent O; Alasmar Z; Osborne S; Bussy A; Costantino M; Fouquet JP; Quesada D; Pastor-Bernier A; Fajardo-Valdez A; Pichet-Binette A; McQuarrie A; Maranzano J; Devenyi GA; Steele CJ; Villeneuve S; ; Dadar M; Chakravarty MM;

White matter hyperintensities (WMHs) are neuroimaging markers widely interpreted as caused by cerebral small vessel disease, yet emerging evidence suggests that a subset may have a neurodegenerative etiology. Current imaging methods have lacked the specificity to disentangle biological processes ...

Article GUID: 40585093

Author(s): Smith EE; Phillips NA; Feldman HH; Borrie M; Ganesh A; Henri-Bhargava A; Desmarais P; Frank A; Badhwar A; Barlow L; Bartha R; Best S; Bethell J; Bhangu J; Black SE; Bocti C; Bronskill SE; Burhan AM; Calon F; Camicioli R; Campbell B; Coll ...

Lecanemab and donanemab are monoclonal antibody therapies that remove amyloid-beta from the brain. They are the first therapies that alter a fundamental mechanism, amyloid-beta deposition, in Alzheimer disease (AD). To inform Canadian decisions on approval and use of these drugs, the Canadian Con ...

Article GUID: 39893139

Author(s): Boucetta S, Salimi A, Dadar M, Jones BE, Collins DL, Dang-Vu TT

Sci Rep. 2016 06 01;6:26782 Authors: Boucetta S, Salimi A, Dadar M, Jones BE, Collins DL, Dang-Vu TT

Article GUID: 27245317